Objective
The inhibition of DPP IV is a validated target in anti-type II diabetic therapy. Existing inhibitors suffer from poor chemical stability or poor selectivity and will be optimised by substituting an amide group for a fluoroolefin group
Fields of science
Call for proposal
Data not availableFunding Scheme
RGI - Research grants (individual fellowships)Coordinator
2610 WILRIJK (ANTWERPEN)
Belgium